Built by former payers, HTA reviewers, and Industry Experts. market access risk assessment
About Us
Where We Started
MARA Rating Company was founded in 2020 by former HTA assessors, payers, and investment-bank analysts who saw billion-dollar deals falter on unrealistic pricing and reimbursement assumptions. Building on decades of combined experience at NICE, ICER, and global-pharma BD and Market Access teams, we set out to bring the rigor of credit rati
MARA Rating Company was founded in 2020 by former HTA assessors, payers, and investment-bank analysts who saw billion-dollar deals falter on unrealistic pricing and reimbursement assumptions. Building on decades of combined experience at NICE, ICER, and global-pharma BD and Market Access teams, we set out to bring the rigor of credit ratings to market-access risk—so capital is deployed with eyes wide open.
Why We Exist
Our mission is to make life-science investments more predictable and patient access more efficient. We deliver transparent, data-driven ratings that quantify pricing and reimbursement risk, empowering companies and investors to move decisively—whether that means acquiring, partnering, or reallocating capital.
Our Values
Our Values
- Independence: Free from advisory conflicts—our ratings speak only to the evidence.
- Evidence First: Proprietary payer data and HTA analytics underpin every score.
- Impact-Driven: We measure success by smarter deals and faster patient access.